000127700 001__ 127700
000127700 005__ 20241125101158.0
000127700 0247_ $$2doi$$a10.37201/req/007.2023
000127700 0248_ $$2sideral$$a134649
000127700 037__ $$aART-2023-134649
000127700 041__ $$aeng
000127700 100__ $$aGarcía-Fernández, Sergio
000127700 245__ $$aActivity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
000127700 260__ $$c2023
000127700 5060_ $$aAccess copy available to the general public$$fUnrestricted
000127700 5203_ $$aObjectives. To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 – 2020. Methods. Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints. Results. In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam. Conclusions. Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients’ location (ICU or non-ICU scenarios).
000127700 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000127700 590__ $$a1.9$$b2023
000127700 592__ $$a0.399$$b2023
000127700 591__ $$aPHARMACOLOGY & PHARMACY$$b231 / 354 = 0.653$$c2023$$dQ3$$eT2
000127700 593__ $$aMedicine (miscellaneous)$$c2023$$dQ3
000127700 591__ $$aMICROBIOLOGY$$b130 / 161 = 0.807$$c2023$$dQ4$$eT3
000127700 593__ $$aPharmacology$$c2023$$dQ3
000127700 593__ $$aMicrobiology (medical)$$c2023$$dQ3
000127700 594__ $$a2.9$$b2023
000127700 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000127700 700__ $$aCalvo, Jorge
000127700 700__ $$aCercenado, Emilia
000127700 700__ $$aSuárez-Barrenechea, Ana Isabel
000127700 700__ $$aFernández-Billón, María
000127700 700__ $$aCastillo, Francisco Javier
000127700 700__ $$aGálvez-Benítez, Lydia
000127700 700__ $$aTubau, Fe
000127700 700__ $$aFigueroa Cerón, Ruth Esther
000127700 700__ $$aHernández-Cabezas, Alicia
000127700 700__ $$aGonzález Romo, Fernando
000127700 700__ $$aFariñas, María Carmen
000127700 700__ $$aGómez, María
000127700 700__ $$aDíaz-Regañón, Jazmín
000127700 700__ $$aCantón, Rafael
000127700 773__ $$g36, 3 (2023), 302-309$$pRev. esp. quimioter.$$tRevista española de quimioterapia$$x0214-3429
000127700 8564_ $$s592380$$uhttps://zaguan.unizar.es/record/127700/files/texto_completo.pdf$$yVersión publicada
000127700 8564_ $$s3192100$$uhttps://zaguan.unizar.es/record/127700/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000127700 909CO $$ooai:zaguan.unizar.es:127700$$particulos$$pdriver
000127700 951__ $$a2024-11-22-12:10:36
000127700 980__ $$aARTICLE